Top Markets
Coin of the day
Pell Bio-Med Technology Co., Ltd. Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd.

6949
Rang in Aktien #4991
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Aktienkurs
$47.38
Zuletzt synchronisiert: 2026-08-26
Marktkapitalisierung
$3.11B
Veränderung (1 Tag)
9.96%
Veränderung (1 Jahr)
238.59%
Land
TW
Handel Pell Bio-Med Technology Co., Ltd. (6949)

Kategorie

Kursverlauf für Pell Bio-Med Technology Co., Ltd. (6949)
Höchster Schlusskurs: $35.36 am 2026-08-01

Niedrigster Schlusskurs: $2.71 am 2024-03-01
Kursverlauf der Aktie von Pell Bio-Med Technology Co., Ltd. von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 64.40%
2025 354.23%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.35 -12.85%
AU
$764.47 7.08%
CH